Lupus & antiphospholipid syndrome
Identification of IFI44L as a new candidate molecular marker for systemic lupus erythematosus
Authors' conclusion
IFI44L may play an important role in SLE pathology through abnormal regulation of the type I interferon signalling pathway.
Study context
- Population
- Systemic lupus erythematosus (SLE) patients and healthy controls; PBMC mRNA
- Comparison
- SLE patients vs healthy controls
- Outcome
- Differentially expressed genes and IFI44L expression, SLE vs healthy controls
Methodological detailswhole-genome mRNA sequencing, RT-qPCR validation, ROC analysis, in vitro cell assays
- Whole-genome mRNA sequencing
- RT-qPCR validation
- ROC analysis
- In vitro cell assays
Main finding
As reported in the abstract
Genes significantly up-regulated in SLE vs healthy controls
122
Genes significantly down-regulated in SLE vs healthy controls
34
Further findings
| Outcome | P value |
|---|---|
| IFI44L expression, male vs female SLE patients | P < 0.05 |
Diagnostic value of IFI44L for SLE (ROC)
- ROC analyses proved IFI44L may have diagnostic value for SLE
Correlation of IFI44L expression with clinical indicators
- Significantly correlated with platelets, mean platelet volume, red blood cell distribution width to platelet ratio, complement component 3 and CRP (p<0.05)
In vitro effects of IFI44L under high interferon (IFN)
- IFI44L resists the proapoptotic effect of IFN-α and improves cell proliferation activity
Original publication
Identification of IFI44L as a new candidate molecular marker for systemic lupus erythematosus. Clin Exp Rheumatol. Published 3 November 2021. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →